Blood test could guide lung cancer treatment in new trial
NCT ID NCT07661173
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a drug called firmonertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study uses a blood test (ctDNA) to decide if treatment should be adjusted over time. About 154 participants will receive firmonertinib alone or with chemotherapy and/or bevacizumab. The goal is to see if this personalized approach helps control the cancer longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Firmonertinib (a targeted drug for EGFR-mutated lung cancer, sometimes combined with chemotherapy or bevacizumab)
- What this could lead to
- If successful, this could show that adjusting treatment based on ctDNA (a blood test) improves how long people live without their cancer getting worse.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 154 people. It may not prove that ctDNA-guided therapy is better than standard care, and side effects from the drug combinations are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?